Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Reumatismo ; 74(1)2022 May 03.
Article in English | MEDLINE | ID: covidwho-1835040

ABSTRACT

The current coronavirus disease 2019 (COVID-19) pandemic is a global challenge with strong medical and socioeconomic implications. Hopes have been placed in the development of various vaccines. As the vaccination campaign is in progress, adverse effects need to be monitored closely. Possible side effects range from minor events to more serious manifestations. In this article, we describe two cases of erythema nodosum (EN) after COVID-19 vaccination in two previously healthy female patients of 59 and 51 years, respectively. Most of the usual etiologies of EN were excluded by laboratory testing. EN was successfully treated with corticosteroids. Remarkably, in the first case, a relapse occurred 48 hours after the second dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. In this case series, we describe two unusual occurrences of EN after vaccination with an mRNA COVID-19 vaccine and a viral vector vaccine, respectively, and we discuss the available related literature.


Subject(s)
COVID-19 , Erythema Nodosum , Viral Vaccines , COVID-19 Vaccines/adverse effects , Erythema Nodosum/chemically induced , Female , Humans , SARS-CoV-2 , Viral Vaccines/adverse effects
2.
J Eur Acad Dermatol Venereol ; 36(8): 1292-1299, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1807159

ABSTRACT

BACKGROUND: Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. OBJECTIVES: A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. METHODS: Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. RESULTS: One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. CONCLUSIONS: Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.


Subject(s)
COVID-19 , Dermatitis, Atopic , Eczema , Antibodies, Monoclonal, Humanized , COVID-19/drug therapy , Dermatitis, Atopic/drug therapy , Double-Blind Method , Humans , Pandemics , Prospective Studies , Pruritus , SARS-CoV-2 , Severity of Illness Index , Treatment Outcome
3.
European Transport-Trasporti Europei ; - (83):14, 2021.
Article in English | Web of Science | ID: covidwho-1689502

ABSTRACT

The 2020-2021 pandemic has changed everyday mobility for part of the world. One of the main elements of change is the consolidation of distance working, which further prompted communications without mobility. The emergency-induced reduction of systematic travel demand has been counterbalanced by the increased volume of web traffic. As a result, communications which formerly required mobility have been regularly performed virtually during the lockdowns. This paper quantifies this phenomenon, with a focus on the Italian city of Turin, in Italy, which was one of the first countries hit by COVID-19, soon after China Local mobility data trends before and during the lockdown are presented and compared. Implications for the "new normal" ahead are discussed. The paper provides directions for further transport policies, with the aim of advancing knowledge of this transportation topic.

4.
J Eur Acad Dermatol Venereol ; 35(10): e647-e649, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1345980
SELECTION OF CITATIONS
SEARCH DETAIL